Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Up 97.4% in April

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 46,010 shares, a growth of 97.4% from the April 15th total of 23,312 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily volume of 31,445 shares, the short-interest ratio is currently 1.5 days.

Neuphoria Therapeutics Stock Down 0.2%

NASDAQ NEUP opened at $4.72 on Tuesday. The company has a market capitalization of $25.45 million, a price-to-earnings ratio of -0.43 and a beta of 0.72. The stock has a fifty day simple moving average of $4.72 and a 200 day simple moving average of $4.38. Neuphoria Therapeutics has a twelve month low of $3.64 and a twelve month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Research analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Neuphoria Therapeutics

A number of institutional investors have recently bought and sold shares of the company. AdvisorShares Investments LLC boosted its position in Neuphoria Therapeutics by 15.8% during the first quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock valued at $632,000 after acquiring an additional 21,173 shares during the last quarter. XTX Topco Ltd bought a new stake in Neuphoria Therapeutics during the fourth quarter valued at $47,000. Ikarian Capital LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter valued at $184,000. Boothbay Fund Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter valued at $54,000. Finally, Bridgeway Capital Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter valued at $57,000. Institutional investors own 15.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on NEUP. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright downgraded Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Neuphoria Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.